Literature DB >> 24591385

Novel therapeutic use of Versajet for intestinal mucormycosis.

William Calvert1, Dhanya Mullassery, Rajeev Shukla, Graham Lamont.   

Abstract

We describe the case of a 17-year-old boy who developed intestinal mucormycosis from Rhizophus oryzae (order Mucorales) following chemotherapy for the management of acute myeloid leukaemia. He underwent a hemicolectomy and further surgery utilising the pressure washing of Versajet to debride colonised fungal collections from the psoas muscle limiting the amount of surgical debridement needed.

Entities:  

Mesh：

Year:  2014        PMID： 24591385      PMCID： PMC3948008          DOI： 10.1136/bcr-2013-202773

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  4 in total

Review 1.  Epidemiology and treatment of mucormycosis.

Authors:  Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Future Microbiol       Date:  2013-09       Impact factor: 3.165

2.  Intestinal mucormycosis: a rare entity in pediatric oncology.

Authors:  Nita Radhakrishnan; Satya Prakash Yadav; Jaswinder Oberoi; Rajeev Kulshreshta; Sunita Bhalla; Anupam Sachdeva
Journal:  Pediatr Hematol Oncol       Date:  2013-02-14       Impact factor: 1.969

3.  Successful treatment of disseminated mucormycosis in a neutropenic patient with T-cell acute lymphoblastic leukaemia.

Authors:  Chelsea Guymer; Sanjeev Khurana; Ram Suppiah; Iain Hennessey; Celia Cooper
Journal:  BMJ Case Rep       Date:  2013-07-31

Review 4.  Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Authors:  Anna Skiada; Fanny Lanternier; Andreas H Groll; Livio Pagano; Stephan Zimmerli; Raoul Herbrecht; Olivier Lortholary; George L Petrikkos
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.